Chronic Active Antibody Mediated Rejection clinical trials

Explore recruiting chronic active antibody mediated rejection clinical trials.

Recruiting chronic active antibody mediated rejection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Active Antibody Mediated Rejection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Allogeneic adipose tissue-derived Mesenchymal stromal cells for the treatment of chronic-active antibody mediated rejection in Kidney transplant recipients

Denmark

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients with Antibody-Mediated Rejection after Kidney Transplantation

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized controlled open-label multicenter study to assess the efficacy of TCZ in treatment of late/chronic active antibody-mediated rejection in kidney transplant recipients

Sweden, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Chronic Active Antibody Mediated Rejection trials by city

Chronic Active Antibody Mediated Rejection in Toronto Chronic Active Antibody Mediated Rejection in Vancouver Chronic Active Antibody Mediated Rejection in Montreal Chronic Active Antibody Mediated Rejection in Calgary Chronic Active Antibody Mediated Rejection in Edmonton Chronic Active Antibody Mediated Rejection in Ottawa Chronic Active Antibody Mediated Rejection in Winnipeg Chronic Active Antibody Mediated Rejection in Quebec City Chronic Active Antibody Mediated Rejection in Hamilton Chronic Active Antibody Mediated Rejection in Kitchener Chronic Active Antibody Mediated Rejection in London Chronic Active Antibody Mediated Rejection in Halifax Chronic Active Antibody Mediated Rejection in New York Chronic Active Antibody Mediated Rejection in Los Angeles Chronic Active Antibody Mediated Rejection in Chicago Chronic Active Antibody Mediated Rejection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease